Fresh perspectives in chronic constipation and other functional bowel disorders.
Functional bowel disorders (FBDs) such as chronic constipation and irritable bowel syndrome-constipation predominant (IBS-C) often share symptoms, but thanks to advances such as the Rome III criteria, diagnosis of these conditions in the absence of alarm features can be relatively straightforward. Empiric treatment is recommended for most patients, with diagnostic testing reserved for those with alarm symptoms. Most current therapies for constipation are indicated for patients with occasional symptoms, with only lubiprostone and tegaserod (restricted) indicated for chronic constipation. Therapies for IBS-C also are limited. However, ongoing research provides promise for improved outcomes in patients with FBDs.
Cash
Brooks D
BD
Gastroenterology Division and Colon Health Initiative, National Naval Medical Center, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA.
Chang
Eugene
E
Talley
Nicholas J
NJ
Wald
Arnold
A
D000328:Adult; D000527:Alprostadil / Q000031:analogs & derivatives / Q000627:therapeutic use; D002400:Cathartics; D018118:Chloride Channels / Q000502:physiology; D002908:Chronic Disease; D002985:Clinical Protocols; D003248:Constipation / Q000175:diagnosis / Q000503:physiopathology / Q000628:therapy; D003672:Defecation; D005227:Fatty Acids / Q000627:therapeutic use; D006801:Humans; D043183:Irritable Bowel Syndrome / Q000175:diagnosis / Q000628:therapy; D000068238:Lubiprostone; D008297:Male; D008365:Manometry; D017060:Patient Satisfaction; D016896:Treatment Outcome
D002400:Cathartics; D018118:Chloride Channels; D005227:Fatty Acids; D000068238:Lubiprostone; D000527:Alprostadil